How Much Does Breast biopsy Cost in China?
Breast biopsy in China typically costs from $600 to $1,200. The final price depends on biopsy method, imaging guidance, pathology tests, and facility type. Examining one or both breasts also changes procedure and lab costs. Beijing, Shanghai, and Guangzhou offer public and private care options. Compared with the US, patients save around 72%. The average US price is $3,200.
- Biopsy method: Fine-needle aspiration generally costs less; vacuum-assisted sampling uses specialized probes.
- Imaging guidance: MRI-guided biopsies can cost more because they require specialized imaging equipment.
- Pathology tests: ER, PR, HER2, or Ki-67 testing adds lab work beyond basic tissue review.
- Facility type: Private or VIP care may cost more, reflecting private rooms, interpreters, and concierge help.
- Breast coverage: Examining both breasts adds procedure and lab work compared with examining one.
Bookimed Expert Insight: For patients comparing costs, language support and travel help can add practical value. Fuda Cancer Hospital in Guangzhou holds Joint Commission International (JCI) accreditation. It offers interpreters and free airport transfers. The hospital has treated over 30,000 patients from more than 100 countries. This may help international patients plan logistics alongside a biopsy inquiry. Its oncology focus makes it relevant for patients seeking cancer-related care.
| China | Turkey | Austria | |
|---|---|---|---|
| Breast biopsy | from $600 | from $800 | ≈ $650 |
Your Benefits and Guarantees with Bookimed
Transparent Prices & Flexible Installments
No hidden fees – just official clinic prices. Pay at the clinic for Breast biopsy upon arrival and use a flexible installment plan if needed.
Verified Clinics & Doctors Only
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Breast biopsy and have the necessary licenses to serve international patients worldwide.
Free 24/7 Assistance
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Breast biopsy journey.

Your personal Bookimed medical coordinator
- Supports you at every stage
- Helps choose the right clinic and doctor
- Ensures quick and convenient access to information
Discover the Best Breast biopsy Clinics in China: 1 Verified Option and Prices
Our Doctors
View all Doctors
Liao Zhengyin
Chief physician and professor. Grade 1 Expert at the Cancer Center, West China Hospital, Sichuan University (ranked No. 2 in China). Completed a postdoctoral fellowship in interventional radiology at the Chinese PLA General Hospital. Leads multidisciplinary team (MDT) care for complex tumors. Expert in minimally invasive interventional oncology for liver, lung, and pancreatic cancers.
Accreditations: Council Member, WATA. Member of CACA and CMDA committees on intervention, ablation, radioactive seeds, and pain. In 2023, inaugural director member, Palliative Care Committee, Sichuan MDA. Editorial board member of the Chinese Journal of Interventional Imaging and Therapy. Editorial board member of the Chinese Journal of Pain Medicine.
Leads 2 provincial S&T projects and 2 NSFC projects. Has 40+ papers, with 30+ as first or corresponding author. Highest impact factor: 10.73. Hepatocellular carcinoma (HCC) cohort: TACE + lenvatinib vs TACE + sorafenib. OS 18.97 vs 10.77 months. PFS 10.6 vs 5.4 months. ORR 66.8% vs 33.3%.

Luo Xiaoping
Professor Luo Xiaoping is a nationally recognized interventional radiologist and a leading authority in Western China. He began pioneering vascular interventions in the early 1990s. He helped found the Interventional Group at the Second Affiliated Hospital of Chongqing Medical University.
He has completed over 100,000 interventional procedures, including about 4,000 complex cases. His key skills include TACE for hepatocellular carcinoma, Budd–Chiari interventions, TIPS, and single-stage bilateral stenting for hilar biliary obstruction, with success rates near 100%. He has been a master’s supervisor since 2007. He has trained many physicians, guided complex cases at more than 40 major hospitals across Western China, and helped build interventional programs. He has published 32 papers as first or corresponding author (22 CSCD core, 4 Chinese core, 6 CSCD extended).

Xiao Yueyong
Professor Xiao Yueyong is Chief Physician in the Department of Radiological Diagnosis at the Chinese PLA General Hospital. He is a leading expert in minimally invasive interventional oncology. He serves as the inaugural President of WATA (2025–). He is President of the International (2020–) and Asian (2012–) Societies of Cryotherapy. He is also Deputy Head of the NHC Expert Group on tumour ablation regulations (2009–).
He has performed over 100,000 CT/MRI‑guided minimally invasive procedures. His work covers chemical ablation, RFA, MWA, cryoablation, and NanoKnife (IRE). He introduced and advanced NanoKnife ablation in China. He led the first national standards for tumour cryoablation and NanoKnife.
Honors include the National Special Contribution Award (Lifetime Honorary). He received First Prize from the Chinese Medicine Education Association (2021). He received two Second Prizes for Military Medical Achievements (2016, 2018) and two Second Prizes from the China Anti‑Cancer Association (2019, 2022). He was named Asian Ablation Master. His research record includes 13 Chinese patents. He is the principal investigator for four NSFC projects and one MOST subject. He has published over 200 papers, with over 110 as first or corresponding author and over 40 in SCI journals. He has led over 10 ablation guidelines or consensus statements.

Hou Jinlin
Professor and Chief Physician. Director of Gynecologic Oncology. PhD in Gynecologic Oncology from the Cancer Hospital, Chinese Academy of Medical Sciences. MSc in Obstetrics and Gynecology from Peking Union Medical College Hospital. Nearly 30 years of clinical experience. Published in SCI and core journals. Co‑author of two gynecologic oncology monographs.
Specializes in standardized diagnosis and comprehensive treatment of ovarian, cervical, and endometrial cancers. Provides surgery, chemotherapy, targeted therapy, immunotherapy, and intraperitoneal hyperthermic perfusion. Pioneer of single‑port laparoscopy at her hospital. Also performs multi‑port laparoscopy, open surgery, and hysteroscopic procedures for benign gynecologic disease.
Affiliations: Youth Director, Chinese Anti‑Cancer Association. Youth Member, Gynecologic Oncology Committee, Fujian Anti‑Cancer Association. Member, Peritoneal Tumor Committee, Fujian Anti‑Cancer Association. Youth Member, Obstetrics and Gynecology Committee, Fujian Medical Association.
Video Stories from Bookimed Patients
Share this content
Anna Leonova

